Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation

计划入组 19 人 · 首次发布于 2015 年 11 月 17 日

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

计划入组 3 人 · 首次发布于 2023 年 10 月 17 日

A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment

计划入组 100 人 · 首次发布于 2025 年 1 月 13 日

Exon 53

Exon 45

Exon-52

Cogent Biosciences

United States

KIT COSMETICS PTY LTD

Australia

BEST DENTAL KIT LLC

United States

FDA Accepts Cogent Biosciences' NDA for Bezuclastinib in Advanced Systemic Mastocytosis, PDUFA Set for June 2027

Cogent Bio Presents Bezuclastinib Data Highlighting Long-Term Benefits in Non-Advanced Systemic Mastocytosis

Cogent Biosciences Raises $475.3 Million to Advance Bezuclastinib for Systemic Mastocytosis